Evidence map›Paper›PMID 40687209›Full record

ArticleSurgical case reports2025

Tumor Rupture in a Patient with Recurrent Hepatocellular Carcinoma Following Atezolizumab plus Bevacizumab: A Case Report.

Kazuhiro Tada, Shohei Yoshiya, Takaaki Mori, Ryoichi Narita, Kentaro Iwaki, Sota Nakamura, Yasunari Yamada, Hajime Takaki, Yo-Ichi Yamashita, Kengo Fukuzawa

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kazuhiro TadaDepartment of Surgery, Oita Red Cross Hospital, Oita, Oita, Japan.
Shohei YoshiyaDepartment of Surgery, Oita Red Cross Hospital, Oita, Oita, Japan.
Takaaki MoriDepartment of Radiology, Oita Red Cross Hospital, Oita, Oita, Japan.
Ryoichi NaritaDepartment of Hepato Biliary Pancreatic Internal Medicine, Oita Red Cross Hospital, Oita, Oita, Japan.
Kentaro IwakiDepartment of Surgery, Oita Red Cross Hospital, Oita, Oita, Japan.
Sota NakamuraDepartment of Surgery, Oita Red Cross Hospital, Oita, Oita, Japan.
Yasunari YamadaDepartment of Radiology, Oita Red Cross Hospital, Oita, Oita, Japan.
Hajime TakakiDepartment of Radiology, Oita Red Cross Hospital, Oita, Oita, Japan.
Yo-Ichi YamashitaDepartment of Surgery, Oita Red Cross Hospital, Oita, Oita, Japan.
Kengo FukuzawaDepartment of Surgery, Oita Red Cross Hospital, Oita, Oita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAtezolizumab plus bevacizumab combination therapy (atezo-bev) has been widely used worldwide as the first-line treatment for unresectable hepatocellular carcinoma (HCC). Intratumoral hemorrhage has been reported as a rare adverse event of atezo-bev. However, no previous cases of HCC rupture during atezo-bev have been reported. Herein, we demonstrate a case of tumor rupture in a patient with recurrent HCC following atezo-bev, who was successfully managed with transcatheter arterial embolization (TAE). CASE PRESENTATION: An 80-year-old man with multiple recurrent HCCs (at least 4 lesions with a maximum tumor diameter of 35 mm protruding from the liver surface) developed epigastralgia immediately after the first cycle of atezo-bev. CT revealed a ruptured HCC in the left lateral lobe. TAE was performed, and the patient continued to receive atezo-bev without any subsequent tumor bleeding.

conclusionsTumor rupture should be considered in patients with HCC following atezo-bev treatment.

Indexed as

atezolizumab plus bevacizumabhepatocellular carcinomarupture

Identifiers

PMID40687209
PMCPMC12272953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.